| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/648450 |
| P698 | PubMed publication ID | 19860563 |
| P2093 | author name string | Ebbing Lautenbach | |
| Mark G Weiner | |||
| Warren B Bilker | |||
| Jeff Schein | |||
| Myoung Kim | |||
| Lien Vo | |||
| Marie Synnestvedt | |||
| P2860 | cites work | Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. | Q50788076 |
| Investigation of a nosocomial outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. | Q53861258 | ||
| Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. | Q53891501 | ||
| The importance of appropriate initial antibiotic therapy for hospital-acquired infections. | Q53912918 | ||
| Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). | Q54469153 | ||
| Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients | Q33638960 | ||
| Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review | Q34192576 | ||
| Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study | Q34285984 | ||
| The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting | Q34509624 | ||
| The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa | Q34581987 | ||
| SHEA/APIC guideline: infection prevention and control in the long-term care facility, July 2008. | Q35870420 | ||
| The epidemiology and control of Acinetobacter baumannii in health care facilities | Q36382140 | ||
| Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature | Q36528076 | ||
| The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species | Q36559359 | ||
| Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. | Q36578135 | ||
| Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae | Q43743478 | ||
| Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection | Q43843241 | ||
| Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. | Q44220176 | ||
| Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis | Q46329565 | ||
| The categorization of prior antibiotic use: impact on the identification of risk factors for drug resistance in case control studies | Q46863374 | ||
| P433 | issue | 12 | |
| P921 | main subject | epidemiology | Q133805 |
| Acinetobacter baumannii | Q3241189 | ||
| P304 | page(s) | 1186-1192 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Infection Control and Hospital Epidemiology | Q6029185 |
| P1476 | title | Epidemiology and impact of imipenem resistance in Acinetobacter baumannii | |
| P478 | volume | 30 |
| Q21131125 | "Stormy waters ahead": global emergence of carbapenemases |
| Q50790475 | Acinetobacter baumannii multidrug-resistant strain occurrence in liver recipients with reference to other high-risk groups. |
| Q36569183 | Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes |
| Q27015109 | Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options |
| Q28478751 | Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection |
| Q36022229 | Antibacterial susceptibility patterns and cross-resistance of acinetobacter, isolated from hospitalized patients, southern iran. |
| Q83399830 | Antimicrobial drug resistance in Taiwan |
| Q27024893 | Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside |
| Q64244084 | CLSI based antibiogram profile and the detection of MDR and XDR strains of isolated from urine samples |
| Q53425898 | Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. |
| Q36887794 | Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections |
| Q39038590 | Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges |
| Q36606740 | Clinical and economic outcomes of Acinetobacter vis a vis non-Acinetobacter infections in an Indian teaching hospital |
| Q24632857 | Combating antimicrobial resistance: policy recommendations to save lives |
| Q36638145 | Controlling endemic multidrug-resistant Acinetobacter baumannii in Intensive Care Units using antimicrobial stewardship and infection control |
| Q45796678 | Detection of antibiotic resistant Acinetobacter baumannii in various hospital environments: potential sources for transmission of Acinetobacter infections. |
| Q92651289 | Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review |
| Q35739134 | Economic value of Acinetobacter baumannii screening in the intensive care unit |
| Q36757737 | Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance |
| Q42245284 | Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes |
| Q34077002 | Factors associated with variation in estimates of the cost of resistant infections |
| Q36646107 | Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment |
| Q36156159 | Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii. |
| Q38086340 | Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. |
| Q35328356 | Impact of antimicrobial stewardship programme changes on unnecessary double anaerobic coverage therapy |
| Q35270405 | Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. |
| Q40403794 | Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections |
| Q36457770 | Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis |
| Q48591028 | Management of carbapenem-resistant Acinetobacter baumannii epidemic in an intensive care unit using multifaceted intervention strategy |
| Q36405521 | Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii |
| Q90176689 | Monoclonal IgM Antibodies Targeting Candida albicans Hyr1 Provide Cross-Kingdom Protection Against Gram-Negative Bacteria |
| Q41092223 | Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study |
| Q33645064 | Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit |
| Q37879199 | Status report on carbapenemases: challenges and prospects |
| Q37786162 | The Dilemma of Multidrug-Resistant Gram-Negative Bacteria |
| Q40083502 | The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China |
| Q43827300 | The effect of obesity on clinical outcomes in presumed sepsis: a retrospective cohort study |
| Q34257288 | The impact of inadequate terminal disinfection on an outbreak of imipenem-resistant Acinetobacter baumannii in an intensive care unit |
| Q34634695 | The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections |
| Q36854025 | White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens |
Search more.